Abobotulinumtoxin A

Phase 3Biologic

NNeurology Center of New England P.C.

Abobotulinumtoxin A is one of 5 biologic programs targeting Skin Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin CarcinomaNot yet recruiting

Skin CarcinomaPhase 3

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Skin Carcinoma

#DrugCompanyPhaseTrials

Voltaren

Trexall

Rapamune

PPrism Pharmaceuticals

Tylenol

Abobotulinumtoxin A

NNeurology Center of New England P.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

ApprovedNot yet recruiting

Skin Carcinoma

NCT07720726

Clinical

Trials by Indication[1]

Moderate to Severe Glabellar Lines1 trial

A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

Completed·EEspad Pharmed·Phase 3·NCT06946160·146 enrolled

Spasticity1 trial

" Treating MS Patients With Lower Extremity Spasticity Using Dysport"

Unknown status·NNeurology Center of New England P.C.·Phase 3·NCT03585569·30 enrolled

Skin Carcinoma1 trial

The Impact of Pre-Operative Abobotulinumtoxin-A Injection on Paramedian Forehead Flap Donor Site Scar Aesthetics- A Randomized Controlled Trial

Not yet recruiting·VVanderbilt University Medical Center·Approved·NCT07720726·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Abobotulinumtoxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abobotulinumtoxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abobotulinumtoxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurology Center of New England P.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: NNeurology Center of New England P.C.

Abobotulinumtoxin A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Moderate to Severe Glabellar Lines1 trial

Spasticity1 trial

Skin Carcinoma1 trial

References

Drug Info

Quick Facts

Related News